SDZ NKT 343

• UNSPSC Description:

  SDZ NKT 343 is a selective, orally active NK1 receptor antagonist with an IC50 of 0.62 nM against human NK1 receptor. SDZ NKT 343 has good analgesic activity[1][2].

• Target Antigen:

  Neurokinin Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/sdz-nkt-343.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(NC([C@H]1N(C(NC2=CC=CC=C2[N+]([O-])=O)=O)CCC1)=O)[C@H](CC3=CC=C4C=CC=CC4=C3)N(C)CC5=CC=CC=C5

• Molecular Weight:

  579.65

• References & Citations:

  [1]Walpole CS, et al. Comparative, general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist. Br J Pharmacol. 1998 May;124(1):83-92. |[2]Walpole C, et al. 2-Nitrophenylcarbamoyl-(S)-prolyl-(S)-3-(2-naphthyl)alanyl-N-benzyl-N - methylamide (SDZ NKT 343), a potent human NK1 tachykinin receptor antagonist with good oral analgesic activity in chronic pain models. J Med Chem. 1998 Aug 13;41(17):3159-73.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 1

• CAS Number:

  180046-99-5